A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology-Reference-Cited by-同舟云学术

A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology

Published:2020-07-30 Issue:10 Volume:23 Page:1176-1185
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Cranmer Holly¹^ORCID,Shields Gemma E.²^ORCID,Bullement Ash³⁴^ORCID

Affiliation:

1. Takeda Pharmaceuticals International Co., London, UK

2. Faculty of Biology, Medicine, and Health, Division of Population Health, Health Services Research, and Primary Care, School of Health Sciences, Manchester Centre for Health Economics, University of Manchester, Manchester, UK

3. Delta Hat Limited, Nottingham, UK

4. School of Health and Related Research, University of Sheffield, Sheffield, UK

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2020.1796360

Reference20 articles.

1. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017

2. Quantifying the burden of informal caregiving for patients with cancer in Europe

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care;PharmacoEconomics;2024-09-07

2. Treatment Effect Waning Assumptions: A Review of National Institute of Health and Care Excellence Technology Appraisals;Value in Health;2024-08

3. Investigation of multiple nosocomial infections using a semi-Markov multi-state model;Antimicrobial Resistance & Infection Control;2024-06-06

4. Informing Structural Assumptions for Three State Oncology Cost-Effectiveness Models through Model Efficiency and Fit;Applied Health Economics and Health Policy;2024-05-21

5. Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens;Risk Management and Healthcare Policy;2024-04